Polymorphisms in an interferon-gamma receptor-1 gene marker and susceptibility to periodontitis

Autor: Bruno G. Loos, DA Fraser, Karl Schenck, U Boman, van Arie Winkelhoff, Zlatko Dembic, U. van der Velden

Publikováno v: Acta Odontologica Scandinavica, 61, 297-302. Informa Healthcare
Fraser, D A, Loos, B G, Boman, U, van Winkelhoff, A J, van der Velden, U, Schenck, K & Dembic, Z 2003, ' Polymorphisms in an interferon-gamma receptor-1 gene marker and susceptibility to periodontitis ', Acta Odontologica Scandinavica, vol. 61, pp. 297-302 . https://doi.org/10.1080/00016350310006168
Acta Odontologica Scandinavica, 61(5), 297-302. Taylor & Francis Ltd

Chronic marginal periodontitis is an inflammatory condition in which the supporting tissues of the teeth are destroyed. Interferon (IFN)-gamma is a cytokine that plays a pivotal role in the defense against infection, and mutations in the gene coding

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d94f9b496946266df70fd19f3a386fa2
https://research.rug.nl/en/publications/533d7b35-e706-494a-aef6-42ba3317c4db

A medium-chain fatty acid analogue prevents hepatosteatosis and decreases inflammatory lipid metabolites in a murine model of parenteral nutrition-induced hepatosteatosis.

Autor: Cho BS; Vascular Biology Program and Department of Surgery, Boston Children's Hospital, Boston, Massachusetts, United States of America.; Harvard Medical School, Boston, Massachusetts, United States of America., Fligor SC; Vascular Biology Program and Department of Surgery, Boston Children's Hospital, Boston, Massachusetts, United States of America.; Harvard Medical School, Boston, Massachusetts, United States of America., Fell GL; Vascular Biology Program and Department of Surgery, Boston Children's Hospital, Boston, Massachusetts, United States of America.; Harvard Medical School, Boston, Massachusetts, United States of America., Secor JD; Vascular Biology Program and Department of Surgery, Boston Children's Hospital, Boston, Massachusetts, United States of America.; Harvard Medical School, Boston, Massachusetts, United States of America., Tsikis ST; Vascular Biology Program and Department of Surgery, Boston Children's Hospital, Boston, Massachusetts, United States of America.; Harvard Medical School, Boston, Massachusetts, United States of America., Pan A; Vascular Biology Program and Department of Surgery, Boston Children's Hospital, Boston, Massachusetts, United States of America., Yu LJ; Vascular Biology Program and Department of Surgery, Boston Children's Hospital, Boston, Massachusetts, United States of America.; Harvard Medical School, Boston, Massachusetts, United States of America., Ko VH; Vascular Biology Program and Department of Surgery, Boston Children's Hospital, Boston, Massachusetts, United States of America.; Harvard Medical School, Boston, Massachusetts, United States of America., Dao DT; Vascular Biology Program and Department of Surgery, Boston Children's Hospital, Boston, Massachusetts, United States of America.; Harvard Medical School, Boston, Massachusetts, United States of America., Anez-Bustillos L; Vascular Biology Program and Department of Surgery, Boston Children's Hospital, Boston, Massachusetts, United States of America.; Harvard Medical School, Boston, Massachusetts, United States of America., Hirsch TI; Vascular Biology Program and Department of Surgery, Boston Children's Hospital, Boston, Massachusetts, United States of America.; Harvard Medical School, Boston, Massachusetts, United States of America., Lund J; Department of Pharmacy, Section for Pharmacology and Pharmaceutical Biosciences, University of Oslo, Oslo, Norway., Rustan AC; Department of Pharmacy, Section for Pharmacology and Pharmaceutical Biosciences, University of Oslo, Oslo, Norway., Fraser DA; NorthSea Therapeutics, Amsterdam, Netherlands., Gura KM; Harvard Medical School, Boston, Massachusetts, United States of America.; Department of Pharmacy and the Division of Gastroenterology and Nutrition, Boston Children's Hospital, Boston, Massachusetts, United States of America., Puder M; Vascular Biology Program and Department of Surgery, Boston Children's Hospital, Boston, Massachusetts, United States of America.; Harvard Medical School, Boston, Massachusetts, United States of America.

Publikováno v: PloS one [PLoS One] 2023 Dec 01; Vol. 18 (12), pp. e0295244. Date of Electronic Publication: 2023 Dec 01 (Print Publication: 2023).

Icosabutate: targeting metabolic and inflammatory pathways for the treatment of NASH.

Autor: Fraser DA; NorthSea Therapeutics, Amsterdam, The Netherlands., Harrison SA; NorthSea Therapeutics, Amsterdam, The Netherlands.; Radcliffe Department of Medicine, University of Oxford, Oxford UK., Schuppan D; Institute of Translational Immunology and Research Center for Immune Therapy, University Medical Center, Mainz, Germany.; Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA, USA.

Publikováno v: Expert opinion on investigational drugs [Expert Opin Investig Drugs] 2022 Dec; Vol. 31 (12), pp. 1269-1278. Date of Electronic Publication: 2022 Dec 28.

A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH.

Autor: Fraser DA; NorthSea Therapeutics, Amsterdam, The Netherlands., Wang X; Institute of Translational Immunology and Research Center for Immune Therapy, University Medical Center, Mainz, Germany., Lund J; Section for Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy, University of Oslo, Norway., Nikolić N; Section for Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy, University of Oslo, Norway., Iruarrizaga-Lejarreta M; OWL Metabolomics, Parque Tecnológico de Bizkaia, Derio, Spain., Skjaeret T; NorthSea Therapeutics, Amsterdam, The Netherlands., Alonso C; OWL Metabolomics, Parque Tecnológico de Bizkaia, Derio, Spain., Kastelein JJP; Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands., Rustan AC; Section for Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy, University of Oslo, Norway., Kim YO; Institute of Translational Immunology and Research Center for Immune Therapy, University Medical Center, Mainz, Germany., Schuppan D; Institute of Translational Immunology and Research Center for Immune Therapy, University Medical Center, Mainz, Germany; Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA, USA. Electronic address: detlef.schuppan@unimedizin-mainz.de.

Publikováno v: Journal of hepatology [J Hepatol] 2022 Apr; Vol. 76 (4), pp. 800-811. Date of Electronic Publication: 2021 Dec 13.

Building capacity for injury prevention: a process evaluation of a replication of the Cardiff Violence Prevention Programme in the Southeastern USA.

Autor: Mercer Kollar LM; Division of Violence Prevention, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia, USA yzq4@cdc.gov., Sumner SA; Division of Violence Prevention, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Bartholow B; Division of Violence Prevention, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Wu DT; School of Medicine, Department of Emergency Medicine, Emory University, Atlanta, Georgia, USA.; Grady Health System, Atlanta, Georgia, USA., Moore JC; Grady Health System, Atlanta, Georgia, USA., Mays EW; Grady Health System, Atlanta, Georgia, USA., Atkins EV; Grady Health System, Atlanta, Georgia, USA., Fraser DA; DeKalb County Police Department, Tucker, Georgia, USA., Flood CE; DeKalb County Police Department, Tucker, Georgia, USA., Shepherd JP; School of Dentistry, Cardiff University, Cardiff, UK.

Publikováno v: Injury prevention : journal of the International Society for Child and Adolescent Injury Prevention [Inj Prev] 2020 Jun; Vol. 26 (3), pp. 221-228. Date of Electronic Publication: 2019 Apr 16.